Back to top
more

Moderna (MRNA)

(Delayed Data from NSDQ)

$63.96 USD

63.96
24,069,834

+2.16 (3.50%)

Updated Jun 18, 2026 04:00 PM ET

After-Market: $64.03 +0.07 (0.11%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.00%
2Buy18.14%
3Hold10.18%
4Sell5.72%
5Strong Sell3.11%
S&P50011.49%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (149 out of 247)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Sanghamitra Saha headshot

4 Good Quality Sector ETFs & Stocks to Buy Right Now

by Sanghamitra Saha

These sectors are extremely well-positioned to survive market shocks. Buy the related ETFs and stocks.

Sweta Jaiswal, FRM headshot

Biotech Stocks, ETFs to Gain on COVID-19 Vaccine & Drug Progress

by Sweta Jaiswal, FRM

The race to introduce a vaccine and drug for COVID-19 is creating near-term opportunities, making the biotech sector a lucrative space for investments.

Zacks Equity Research

The Zacks Analyst Blog Highlights: Moderna, Regeneron Pharmaceuticals, Zoom Video Communications, Peloton Interactive and Costco Wholesale

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Moderna, Regeneron Pharmaceuticals, Zoom Video Communications, Peloton Interactive and Costco Wholesale

Kinjel Shah headshot

Is Pharma the Sector to Bet on in 2020? 2 Big Stocks to Buy

by Kinjel Shah

Here we have highlighted two big pharma stocks that may prove to be good buys. Both these stocks carry a Zacks Rank #1 (Strong Buy) and have seen their share price rise this year.

Sanghamitra Saha headshot

These Medical ETFs & Stocks Deserve a Salute on Health Day

by Sanghamitra Saha

The World Health Day of 2020 puts these medical companies and the related stocks and ETFs in focus.

Zacks Equity Research

Moderna (MRNA) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

Moderna (MRNA) closed at $34.64 in the latest trading session, marking a -0.57% move from the prior day.

Zacks Equity Research

Moderna Stock Surges 78% YTD on Coronavirus Vaccine Progress

by Zacks Equity Research

Moderna (MRNA) is making significant progress in development of coronavirus vaccine. It is actively preparing for a potential phase II study.

Tirthankar Chakraborty headshot

5 Top Stocks to Buy With the $1,200 Coronavirus Stimulus Check

by Tirthankar Chakraborty

A one-time $1,200 cash payment from the federal government is widely expected to arrive around the middle of April. Here's how to use it -

Sanghamitra Saha headshot

Top Leveraged ETFs of Last Week

by Sanghamitra Saha

These leveraged ETFs won last week despite a broader market bloodbath.

Kinjel Shah headshot

Pharma Coronavirus Efforts Continue, Amgen & Incyte Join In

by Kinjel Shah

Amgen (AMGN) signs a deal with Adaptive Biotechnologies to discover antibodies to prevent/treat COVID-19. Incyte/Novartis (NVS) plan to initiate study on Jakafi for COVID-19- associated cytokine storm.